

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 167 355 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
02.01.2002 Bulletin 2002/01

(51) Int Cl.7: **C07D 231/12, A61K 31/415**

(21) Application number: **01106333.6**

(22) Date of filing: **15.03.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **26.06.2000 TR 200001872**

(71) Applicant: **FAKO ILACLARI A.S.**
Levend 80650, Istanbul (TR)


(72) Inventors:
• **Gündüz, Halit**
80650 Levend, Istanbul (TR)
• **Bahar, Mehmet**
80650 Levend, Istanbul (TR)
• **Göktepe, Mehmet**
80650 Levend, Istanbul (TR)

(74) Representative: **Maiwald Patentanwalts GmbH**
Elisenhof Elisenstrasse 3
80335 München (DE)

(54) **A crystalline form of celecoxib**

(57) A new crystalline form of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide of Formula I


designated as Form I and a method for its production.



EP 1 167 355 A1

Description

[0001] This invention relates to the pharmaceutical therapeutic agent 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (celecoxib) of formula I



specifically to a new crystalline form of celecoxib with improved properties. This invention further relates to a method for the production of this crystalline form of the agent.

[0002] Since prostaglandins play a major role in the inflammation process, the discovery of non-steroidal anti-inflammatory drugs (NSAIDs) has focused on the inhibition of prostaglandin production, especially PGG₂, PGH₂ and PGC₂ production. The use of NSAIDs in the treatment of pain and swelling associated with the inflammation tends to cause side effects by affecting other prostaglandin regulated processes. Thus NSAIDs tend to cause significant side effects including ulcers.

[0003] Previous NSAIDs have been found to inhibit some enzymes including cyclooxygenase. Recently, an inducible form of cyclooxygenase associated with inflammation known as cyclooxygenase II (COX-2) or prostaglandin G/M synthase II has been found to exist. This enzyme is more effective in reducing inflammation, causing fewer and less drastic side effects.

[0004] Several compounds selectively inhibiting cyclooxygenase II are described in U.S. Patent Nos. 5 380 738, 5 344 991, 5 393 790, 5 466 823, 5 434 178, 5 474 995, 5 510 368, and International Applications WO 96/06840, 96/03388, 96/03387, 95/15316, 94/15932, 94/27980, 95/00501, 94/13635, 94/20480 and 94/26731.

[0005] Certain substituted pyrazolylbenzenesulfonamides, specifically celecoxib (4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide) as selective COX-2 inhibitor and their preparation have been described in International Application WO 95/15316. In addition, an efficient preparation of 3-haloalkyl-1H-pyrazoles in a one-pot synthesis which is suitable for large-scale process has been described in International Application WO 96/37476.

[0006] International Application No. WO 00/32189 discloses specific celecoxib compositions. In this document a number of problems concerning the formulation of this agent, inter alia, its cohesiveness, low bulk density, low compressibility, poor solubility, etc., are described. According to this document, these disadvantages are caused by the crystal structure of celecoxib. Unformulated celecoxib, which has a crystal morphology that tends to form long cohesive needles, typically fuses into a monolith mass upon compression in a tablet die, which leads to problems in blending the agent uniformly. Further, low bulk density causes problems in processing the small quantities required in the formulation of pharmaceutical compositions.

[0007] It has now surprisingly been discovered that celecoxib may exist at least in two crystalline forms, hereinafter designated as Form I and Form II, having different properties.

[0008] Certain organic compounds can exist in several different crystal forms, which can have different chemical and physical properties, such as density, hardness, flow properties, etc. Therefore, new crystal forms of existing compounds are of great interest.

[0009] The new crystal form of celecoxib reported herein provides improved properties, making it possible to overcome the problems described in the prior art. Since the new crystal form does not have the disadvantages of the known needle-like crystals, it overcomes the problems disclosed e.g. in WO 00/32189.

[0010] The object of the present invention, therefore, is to provide a new crystalline form of celecoxib which avoids the problems produced by the known, needle-like crystalline form.

[0011] The solution of this object is provided by the new crystalline form of celecoxib as disclosed herein, which we have called "Form I" of celecoxib, and by the corresponding production method, as also described herein.

[0012] Crystalline forms are characterised by means of X-ray powder diffraction patterns. For this purpose a PHILIPS PW 1710 based diffractometer was used and Cu-K α -radiation (λ (Cu-K α_1) = 1.54056 Å; λ (Cu-K α_2) = 1.54439 Å) was applied. X-ray diffraction data are provided in terms of 2 θ values and corresponding intensities.

EP 1 167 355 A1

[0013] The crystalline form of celecoxib designated as Form I according to the present invention is characterised by at least the X-ray powder diffractogram data given in table I:

TABLE I:

X-ray Diffraction data of Form I:	
Angle [°2θ]	Rel.int [%]
14.800	69.0
16.050	78.9
17.875	63.7
19.615	100.0
21.455	96.6
22.080	68.1
22.385	65.4
23.425	62.5
25.330	64.5
29.355	60.8

[0014] In a preferred embodiment of the present invention said crystalline form of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide of Form I is further characterised by at least the following further X-ray powder diffractogram data given in table II:

TABLE II:

Further X-ray Diffraction data of Form I:	
Angle [°2θ]	Rel.int [%]
10.670	33.4
10.970	34.0
12.985	32.4
13.855	17.5
18.340	40.4
18.685	40.0
20.425	19.1
20.670	19.0
23.185	48.7
24.510	37.8
24.930	34.5
25.730	22.8
26.915	23.1
27.630	31.5
28.185	26.2
29.955	32.7
30.375	9.9
31.405	9.6
34.915	15.7
35.585	10.9
37.895	17.9
44.070	9.4
45.250	14.5
(in addition to the dominant reflexes of table I).	

[0015] An example of the X-ray diffraction pattern of Form I is shown in Fig. 1.

[0016] The alternative disadvantageous, needle-like crystal form (designated herein as Form II) which is provided

by the methods described in the prior art differs significantly from Form I according to the present invention.

[0017] An example of the X-ray diffraction pattern for the known Form II is shown in fig. 2 and the corresponding data are given in Table III.

TABLE III:

X-ray Diffraction data of Form II	
Angle [°2 θ]	Rel.int [%]
11.025	27.5
13.285	5.9
15.115	16.5
16.415	91.4
17.625	3.2
18.265	3.6
19.785	5.6
21.820	100.00
22.440	16.9
23.500	2.7
24.620	3.0
25.460	2.7
27.280	21.0
29.885	15.6
31.580	1.5
32.815	9.0
35.185	7.4
38.205	5.8
38.415	4.2
39.695	2.5
40.740	3.7
41.285	0.8
42.960	2.4
43.810	2.7
44.820	4.5
45.415	5.0
46.300	4.9


[0018] Further, SEM images of the crystallites of Form I according to the invention and Form II obtained by the production methods known in the prior art clearly illustrate the plate like habit of the crystals of Form I in contrast to the needle like habit of the crystals of Form II; as is illustrated by attached Fig. 3 and 4.

[0019] One of the main disadvantages of the needle-like crystals of Form II mentioned in WO 00/32189 is their low bulk density. It was found, that the crystals of the invention's Form I are distinctly denser in comparison to the crystals of Form II prepared according to the methods as given in International Applications WO 95/15316 and WO 96/37476. The following densities are typical and characteristic for the crystals of Form I and II, respectively:

	Form I	Form II
bulk density	≥ about 0.270 g/ml	about 0.130 g/ml
tap density	≥ about 0.360 g/ml	about 0.180 g/ml

[0020] Consequently, the crystals of Form I are denser than the crystals of Form II, providing improved filtration and drying characteristics. Due to its increased density, better flow properties and lower electrostatic charge, Form I provides further advantages in formulation and capsule preparation.

[0021] The present invention further relates to a method for the production of the crystals of Form I of celecoxib by reacting 1-(4-methylphenyl)-4,4,4-trifluorobutane-1,3-dione of formula II



with 4-sulphonamidophenylhydrazine hydrochloride in a suitable solvent, crystallizing the resulting 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide from the reaction mixture and recrystallizing it from a suitable solvent.

[0022] 1-(4-methylphenyl)-4,4,4-trifluorobutane-1,3-dione may be prepared according to Example 2 Step 1 in International Application WO 95/15316.

[0023] The preparation of celecoxib, according to the present invention, differs from the production described in WO 95/15316 mainly by the crystallization system used.

[0024] Thus, the dione is preferably reacted with 4-sulphonamidophenylhydrazine hydrochloride in isopropanol, instead of absolute ethanol, at reflux temperature. The reaction mixture is treated with activated carbon; after filtering, the product is preferably obtained by crystallizing it by the addition of a non-solvent, especially water (instead of by concentration of the reaction mixture). Finally, the substance is preferably recrystallized from isopropanol and water, instead of methylenechloride/hexane.

[0025] Accordingly, the present invention provides further advantages for the preparation of celecoxib by eliminating methylene chloride, a risk for the environment and human health. In addition, it also eliminates the use of n-hexane which causes an ignition and fire risk due to its electrostatic charge accumulation property. Further, according to the present invention, water replaces n-hexane. The use of isopropanol is a further advantage, since it is commercially available and widely used in chemical industry compared to absolute ethanol. Isopropanol should be anhydrous and may be combined with other hydroxylic solvents. Finally, by precipitating the product from the reaction mixture instead of concentrating the reaction mixture to dryness, a higher purity is achieved.

[0026] In order to obtain crystals of Form I, celecoxib is most preferably prepared by dissolving celecoxib in a suitable solvent system comprising at least one amide solvent, preferably selected from the group comprising N,N-dimethylformamide, NN-dimethylacetamide and/or mixtures thereof, N,N-dimethylformamide being most preferred, from which solution the crystals of Form I are obtained by the addition of a non-solvent, especially water.

[0027] This recrystallization is generally carried out at temperatures of 0 to 80 °C, particularly of 5 to 70 °C, preferably of 10 to 60 °C, more preferably of 15 to 50 °C, most preferably of 20 to 40 °C, e.g., of 25 to 30 °C and/or ambient temperature.

[0028] The present invention further includes crystalline celecoxib of Form I crystallography, obtainable by the above described method of production.

[0029] Further, the present invention includes pharmaceutical preparations, comprising crystalline celecoxib according to the present invention. Pharmaceutical preparations according to the present invention may be adapted for oral administration and are conveniently presented in the form of, e.g., tablets, capsules, dragees or the like. The formulations may contain ingredients like pharmaceutically acceptable carriers, excipients, adjuvants, etc. as they are known in the art.

Example

Step a: 1-(4-methylphenyl)-4,4,4-trifluorobutane-1,3-dione

[0030] 4'-Methylacetophenone was dissolved in methanol (25 ml) under nitrogen atmosphere. To the stirred solution was added 25% sodium methoxide in methanol (12 ml). The reaction mixture was stirred for 5 minutes and ethyltrifluoroacetate (5.5ml) was added. After refluxing under nitrogen atmosphere for 24 hours the mixture was cooled to room temperature and concentrated. 10 % hydrochloric acid (100 ml) was added. The mixture was extracted with ethyl acetate (4 x 75 ml). The combined organic layer was dried over MgSO₄, filtered and concentrated. The product was obtained as an oily residue.

Step b: 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide

[0031] 1-(4-Methylphenyl)-4,4,4-trifluorobutane-1,3-dione (4.14 g) from step a was stirred in isopropanol (75 ml). 4-sulphonamidophenylhydrazine hydrochloride (4.25 g) was added. The reaction mixture was refluxed under nitrogen

EP 1 167 355 A1

atmosphere for 24 hours, cooled to room temperature and filtered, The filtrate was treated with activated carbon at 40-45° C. The product was crystallized by adding water (150 ml). The product was recrystallized from isopropanol and water.

5 Step c: Isolation of Form I

[0032] 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (20 g) from step b was dissolved in N,N-dimethylformamide (80 ml) at room temperature. The product was crystallized by addition of water (200 ml). The reaction mixture was stirred for 30 minutes. The product was isolated by filtration, washed with water (3 x 40 ml) and dried. Yield: 18 g.

[0033] It corresponded to fig. 3 and showed the X-ray diffraction data presented in fig. 1 and tables I and II.

15 Claims

1. Crystalline 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, characterised by at least the following X-ray powder diffractogram reflexes:

Angle [°2 θ]	Rel.int [%]
14.800	69.0
16.050	78.9
17.875	63.7
19.615	100.0
21.455	96.6
22.080	68.1
22.385	65.4
23.425	62.5
25.330	64.5
29.355	60.8

2. The crystalline 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide according to claim 1, characterised by at least the following further X-ray powder diffractogram reflexes:

Angle [°2 θ]	Rel.int [%]
10.670	33.4
10.970	34.0
12.985	32.4
13.855	17.5
18.340	40.4
18.685	40.0
20.425	19.1
20.670	19.0
23.185	48.7
24.510	37.8
24.930	34.5
25.730	22.8
26.915	23.1
27.630	31.5
28.185	26.2
29.955	32.7
30.375	9.9
31.405	9.6
34.915	15.7

(continued)

Angle [°2 θ]	Rel.Int [%]
35.585	10.9
37.895	17.9
44.070	9.4
45.250	14.5

5

10

3. Crystalline 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, especially according to claim 1 or 2,
characterised in that it has

15

a tap density of not less than 0.360 g/ml, and/or
a bulk density of not less than 0.270 g/ml.

20

4. A method for the production of the crystalline substance according to any one of claims 1 to 3,
characterised in that 1-(4-methylphenyl)-4,4,4-trifluorobutane-1,3-dione is reacted with 4-sulphonamidophenylhydrazine hydrochloride in a suitable solvent, the resulting 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide is crystallized from the reaction mixture and is recrystallized by solvent precipitation from a suitable solvent.

25

5. The method according to claim 4,
characterised in that the reaction is carried out in isopropanol.

30

6. The method according to any one of claims 4 or 5,
characterised in that 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide is crystallized from the reaction mixture by the addition of a nonsolvent, especially water.

35

7. The method according to any one of claims 4 to 6,
characterised in that 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide is recrystallized from a solvent system comprising at least one amide solvent.

8. The method according to any one of claims 4 to 7,
characterised in that 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide is recrystallized from a solvent system comprising at least one amide solvent by addition of a non-solvent, especially water, at a temperature between 0°C and 80°C.

40

9. The method according to any one of claims 4 to 8,
characterised in that the amide solvent is selected from the group, comprising N,N-dimethylformamide, N,N-dimethylacetamide and mixtures thereof.

45

10. Crystalline 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide in accordance with claims 1,2 or 3, obtainable by the method of any one of claims 4 to 8.

50

11. A pharmaceutical preparation, comprising crystalline 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide in accordance with any one of claims 1,2,3 or 10.

55

Figure I




Figure 2




Figure 3: SEM image illustrating the plate like habit of the crystals of Form I:




Figure 3

Figure 4: SEM image illustrating the needle like habit of crystals of Form II:




Figure 4



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 10 6333

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 96 37476 A (SEARLE) 28 November 1996 (1996-11-28) * example 1 *	1-11	C07D231/12 A61K31/415
X	WO 95 15316 A (GRANETS MATTHEW J ;MIYASHIRO JULIE M (US); SEARLE & CO (US); TALLE) 8 June 1995 (1995-06-08) * page 64 - page 65, line 7; example 2 *	1-11	
X	PENNING, THOMAS D. ET AL: "Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)" J. MED. CHEM. (1997), 40(9), 1347-1365 , XP002114833 * page 1356, left-hand column, line 18 - line 29 *	1-3,10, 11	
P,X	WO 01 42222 A (MIYAKE PATRICIA J ;FERRO LEONARD J (IL); PHARMACIA CORP (US)) 14 June 2001 (2001-06-14) * page 4 - page 5; example 2 * * page 11 - page 14 * * page 52 - page 57 *	1-11	C07D A61K
P,X	WO 00 42021 A (MERCK FROSST CANADA INC ;TILLYER RICHARD D (CA); DALTON CHAD (CA);) 20 July 2000 (2000-07-20) * page 4; claim 7; example 1 *	1-11	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 22 August 2001	Examiner De Jong, B
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (03.02) (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 10 6333

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

22-08-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9637476 A	28-11-1996	AU 708964 B	19-08-1999
		AU 5873696 A	11-12-1996
		BR 9609043 A	23-02-1999
		CA 2222138 A	28-11-1996
		CN 1190960 A	19-08-1998
		CZ 9703689 A	18-03-1998
		EP 0828717 A	18-03-1998
		JP 11505848 T	25-05-1999
		NO 975387 A	17-12-1997
		NZ 308875 A	30-08-1999
		PL 323492 A	30-03-1998
		US 5910597 A	08-06-1999
		US 5892053 A	06-04-1999
WO 9515316 A	08-06-1995	US 5466823 A	14-11-1995
		US 5521207 A	28-05-1996
		AT 187965 T	15-01-2000
		AU 690609 B	30-04-1998
		AU 1171495 A	19-06-1995
		BR 1100406 A	08-02-2000
		CA 2177576 A	08-06-1995
		CN 1141630 A, B	29-01-1997
		CN 1280125 A	17-01-2001
		CN 1280126 A	17-01-2001
		CZ 9601503 A	11-12-1996
		DE 69422306 D	27-01-2000
		DE 69422306 T	18-05-2000
		DK 731795 T	15-05-2000
		EP 0731795 A	18-09-1996
		EP 0924201 A	23-06-1999
		EP 0922697 A	16-06-1999
		EP 0923933 A	23-06-1999
		ES 2141916 T	01-04-2000
		FI 962249 A	29-05-1996
		GR 3032696 T	30-06-2000
		HK 1013649 A	07-07-2000
		HU 74180 A	28-11-1996
		JP 2000109466 A	18-04-2000
		JP 3025017 B	27-03-2000
		JP 9506350 T	24-06-1997
		KR 229343 B	01-11-1999
		KR 263817 B	16-08-2000
		KR 261669 B	15-07-2000
		LU 90698 A	13-02-2001
		NO 962184 A	29-05-1996
		NZ 276885 A	30-08-1999

EPO FORM P459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 10 6333

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

22-08-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9515316 A		PL 314695 A	16-09-1996
		PT 731795 T	31-05-2000
		RU 2139281 C	10-10-1999
		US 6156781 A	05-12-2000
		US 5510496 A	23-04-1996
		US 5563165 A	08-10-1996
		US 5508426 A	16-04-1996
		US 5516907 A	14-05-1996
		US 5504215 A	02-04-1996
		US 5753688 A	19-05-1998
		US 5760068 A	02-06-1998
		ZA 9409418 A	28-11-1995
WO 0142222 A	14-06-2001	WO 0141536 A	14-06-2001
		WO 0141761 A	14-06-2001
		WO 0141762 A	14-06-2001
		WO 0141760 A	14-06-2001
		WO 0142221 A	14-06-2001
WO 0042021 A	20-07-2000	AU 3028500 A	01-08-2000
		US 6150534 A	21-11-2000
		US 6232472 B	15-05-2001

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82